Cargando…
Evolution of Resistance to Targeted Anti-Cancer Therapies during Continuous and Pulsed Administration Strategies
The discovery of small molecules targeted to specific oncogenic pathways has revolutionized anti-cancer therapy. However, such therapy often fails due to the evolution of acquired resistance. One long-standing question in clinical cancer research is the identification of optimum therapeutic administ...
Autores principales: | Foo, Jasmine, Michor, Franziska |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2766072/ https://www.ncbi.nlm.nih.gov/pubmed/19893626 http://dx.doi.org/10.1371/journal.pcbi.1000557 |
Ejemplares similares
-
Correction: Evolution of Resistance to Targeted Anti-Cancer Therapies during Continuous and Pulsed Administration Strategies
por: Foo, Jasmine, et al.
Publicado: (2009) -
The Impact of Microenvironmental Heterogeneity on the Evolution of Drug Resistance in Cancer Cells
por: Mumenthaler, Shannon M, et al.
Publicado: (2015) -
Evolutionary Modeling
of Combination Treatment Strategies To Overcome Resistance to Tyrosine
Kinase Inhibitors in Non-Small Cell Lung Cancer
por: Mumenthaler, Shannon M., et al.
Publicado: (2011) -
Fitness Conferred by BCR-ABL Kinase Domain Mutations Determines the Risk of Pre-Existing Resistance in Chronic Myeloid Leukemia
por: Leder, Kevin, et al.
Publicado: (2011) -
Eradication of Chronic Myeloid Leukemia Stem Cells: A Novel Mathematical Model Predicts No Therapeutic Benefit of Adding G-CSF to Imatinib
por: Foo, Jasmine, et al.
Publicado: (2009)